The VALVE-AI Trial

NARecruitingINTERVENTIONAL
Enrollment

8,648

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions
Valvular Heart Disease Patients
Interventions
DIAGNOSTIC_TEST

AI-ECG driven echocardiography

The intervention utilizes a previously validated deep learning model based on 12-lead electrocardiogram (ECG) data to screen for moderate-to-severe valvular heart diseases (VHD). The model processes raw ECG signals and integrates age and sex to enhance prediction. (doi: 10.18632/aging.205835.) Participants identified as high-risk for any moderate-to-severe VHD by the algorithm of artificial intelligence-powered electrocardiogram (AI-ECG) in this intervention arm will receive transthoracic echocardiography to confirm diagnosis and guide further management.

Trial Locations (1)

Unknown

RECRUITING

Tri-Service General Hospital, Taipei

All Listed Sponsors
lead

National Defense Medical Center, Taiwan

OTHER

NCT07023510 - The VALVE-AI Trial | Biotech Hunter | Biotech Hunter